Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial

By sjmartinez • May 6, 2024

Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, Sitbon O, Vachiéry JL, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Osterhout R, Bruey JM, Elman E, Tompkins CA, Parsley E, Aranda R, Zisman LS, Ghofrani HA; TORREY Study Investigators. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2024 May 2:S2213-2600(24)00072-9. doi: 10.1016/S2213-2600(24)00072-9. Epub ahead of print. PMID: 38705167.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

Dwyer Orr L, Vadagam P, Vanderpoel J, Patel MI, Basu Roy U, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Differences[...]

Effect of biologic use on the development of psoriatic arthritis: A population-based study

Miao KL, Huang MY, Guo L, Lung K, Armstrong AW. Effect of biologic use on the development of psoriatic arthritis: A population-based study. J Eur[...]

Correction: The PROMIS-16 reproduces the PROMIS-29 physical and mental health summary scores accurately in a probability-based internet panel

Hays RD, Herman PM, Rodriguez A, Slaughter M, Zeng C, Edelen MO. Correction: The PROMIS-16 reproduces the PROMIS-29 physical and mental health summary scores accurately[...]